Todas las investigaciones
ReclutamientoFASE3INTERVENCIONISTA

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

This study is for adults with a condition called Immune Thrombocytopenia (ITP). ITP causes your body to destroy tiny blood cells called platelets, which help your blood clot. This can lead to bruising and bleeding easily. We are trying to find out if a new medicine called mezagitamab can help keep platelet counts stable in people with ITP. Participants will receive either mezagitamab or a dummy medicine (placebo) by injection under the skin for up to 6 months. We then look at how each group's platelet counts change. Some people might also have the chance to continue taking mezagitamab after the main study ends.

De un vistazo

Estado
Reclutamiento
Fase
FASE3
Patrocinador
Takeda
Objetivo de inscripción
171
Inicio
27 Feb 2025
Estimación de finalización
16 Mar 2028

¿De qué trata este estudio?

This study is focused on a condition called Immune Thrombocytopenia, or ITP. If you have ITP, your body's defence system, called the immune system, mistakenly attacks and destroys your platelets. Platelets are really important because they are tiny cells in your blood that help it to clot and stop bleeding. When you don't have enough platelets, you might bruise easily, notice small red spots on your skin, or experience nosebleeds or gum bleeding.

We are looking into a new medicine called mezagitamab. The main goal of this study is to see if mezagitamab can effectively help keep your platelet count at a healthy and stable level compared to a placebo. A placebo looks exactly like the real medicine but doesn't contain any active ingredients. This helps us understand if any improvements are truly due to the new medicine.

Participants in the study will receive mezagitamab or the placebo as an injection just under the skin. This treatment will continue for up to six months. We hope this study will give us important information about whether mezagitamab could be a helpful new treatment option for people living with ITP.

Puntos clave

  • This study is testing a new medicine (mezagitamab) for adults with ITP.
  • It aims to see if mezagitamab can help keep platelet counts stable.
  • You might receive the new medicine or a dummy treatment (placebo).
  • Treatment is given by injection under the skin for up to 6 months.
  • Regular clinic visits are required to monitor your health.
  • There's a chance to continue with mezagitamab after the main study, if eligible.

¿Quién puede ser elegible?

This study is for adults aged 18 and over who have been diagnosed with ITP for at least a year. You would need to have shown a good response to an ITP treatment in the past (but not a type called a TPO-RA), and your current platelet count should be less than 30,000.

You also need to have tried and not responded well to or couldn't tolerate at least two different types of ITP treatment – one first-line treatment (like steroids) and at least one second-line treatment (like TPO-RAs, rituximab, fostamatinib, or mycophenolate). If you're using other ITP treatments, they need to have been at a steady dose for at least a month before the study starts and expected to stay the same throughout.

You wouldn't be able to join if your ITP is due to another medical condition (called secondary ITP), if you've had a blood clot or stroke in the last year, have had your spleen removed, or have certain active infections like Hepatitis B, C, or HIV. A history of certain cancers would also mean you couldn't take part.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. I am 18 years old or older.
  2. I have been diagnosed with ITP for at least one year.
  3. My current platelet count is less than 30,000.
  4. I have tried at least two different ITP treatments (like steroids and another type) in the past, and they either didn't work well enough or caused too many side effects.
  5. I have not had a blood clot or stroke in the past year.
  6. I do not have Hepatitis B, C, or HIV.
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you join the study, you'll receive the study medicine (mezagitamab or a placebo) as an injection under your skin for up to 6 months. Throughout this time, you'll need to visit the study clinic several times. These visits will involve checks to see how you are doing, including blood tests to measure your platelet count and general health. The doctors will also ask you questions about any side effects you might be experiencing.

After the main study finishes, or if the treatment doesn't seem to be working for you after 16 weeks, you may get the chance to join a follow-on study. In this continuation study, eligible participants would receive mezagitamab openly, meaning they would know they are getting the active medicine. The doctors will explain more about this if it applies to you.

Riesgos y beneficios potenciales

Taking part in a clinical trial can have potential benefits, like gaining access to a new medicine before it's widely available, and helping doctors learn more about ITP and its treatment. However, there are also potential risks, such as side effects from the medicine or the extra clinic visits required. You might receive the placebo, which means you won't get the active study drug. Your health will be carefully monitored throughout the study, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (124)

  • Genesis Cancer and Blood Institute - SCRI
    Código postal verificado
    Hot Springs, United States· Reclutamiento
  • USC Norris Comprehensive Cancer Center - Keck Medicine of USC
    Código postal verificado
    Los Angeles, United States· Reclutamiento
  • University of California San Diego Center for Bleeding and Clotting Disorders
    Código postal verificado
    San Diego, Estados Unidos· Aún no reclutando
  • Rocky Mountain Cancer Center
    Código postal verificado
    Denver, Estados Unidos· Retirado
  • Georgetown University Medical Center - Lombardi Comprehensive Cancer Center
    Código postal verificado
    Washington D.C., Estados Unidos· Reclutamiento
  • Emory University
    Código postal verificado
    Atlanta, Estados Unidos· Reclutamiento
  • Innovative Hematology, Inc.
    Código postal verificado
    Indianápolis, Estados Unidos· Reclutamiento
  • The University of Iowa
    Código postal verificado
    Iowa City, Estados Unidos· Reclutamiento
  • University Of Louisville Brown Cancer Center
    Código postal verificado
    Louisville, Estados Unidos· Reclutamiento
  • American Oncology Partners of Maryland, PA
    Código postal verificado
    Bethesda, Estados Unidos· Reclutamiento
  • Hospital General de Massachusetts
    Código postal verificado
    Boston, Estados Unidos· Reclutamiento
  • University of Massachusetts Chan Medical School
    Código postal verificado
    Worcester, Estados Unidos· Completado

Preguntas comunes

What is ITP?

ITP (Immune Thrombocytopenia) is a condition where your immune system mistakenly destroys your platelets, which are tiny cells that help your blood clot. This can lead to easy bruising and bleeding.

What is mezagitamab?

Mezagitamab is the new medicine being tested in this study. We want to see if it can help keep platelet counts stable in people with ITP.

¿Qué es un placebo?

A placebo is a dummy medicine. It looks exactly like the study medicine but contains no active ingredients. It helps doctors work out if the real medicine is having an effect.

How will I receive the study medicine?

The study medicine (mezagitamab or placebo) will be given as an injection just under your skin.

¿Cuánto tiempo estaré en el estudio?

You will receive the study medicine for up to 6 months, and there will be several follow-up visits during and after this period.

Cómo obtener más información

Takeda Contact

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "A Study of Mezagitamab in Adults With Chronic Primary Immune…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.